Liquidia Corporation (MUN:LT4)
| Market Cap | 4.64B +121.0% |
| Revenue (ttm) | 547.61M +798.4% |
| Net Income | -82.94M |
| EPS | -0.97 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 16.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 51.64 |
| Previous Close | 51.64 |
| Day's Range | 51.64 - 51.64 |
| 52-Week Range | 24.76 - 79.52 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 10, 2026 |
About Liquidia
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L6... [Read more]
Financial Performance
In 2025, Liquidia's revenue was $158.32 million, an increase of 1031.18% compared to the previous year's $14.00 million. Losses were -$68.92 million, -46.28% less than in 2024.
Financial numbers in USD Financial StatementsNews
Liquidia Transcript: Jefferies Global Healthcare Conference
YUTREPIA exceeded 30% market share by end-September, with management targeting continued growth and over 50% operating margins in 2027. The pipeline plan includes 10 trials, three registrational, and L606 data targeted for 2029.
Liquidia assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield assumed coverage of Liquidia (LQDA) with a Buy rating and $76 price target The company’s October settlement with United Therapeutics (UTHR) “opens a new chapte...
Liquidia upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Ryan Deschner upgraded Liquidia (LQDA) to Strong Buy from Outperform with a price target of $77, up from $53. Liquidia’s Yutrepia launch continues to exceed expectations, with…
Liquidia upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Ryan Deschner upgraded Liquidia (LQDA) to Strong Buy from Outperform with a price target of $77, up from $53.
Liquidia price target raised to $54 from $42 at BofA
BofA raised the firm’s price target on Liquidia (LQDA) to $54 from $42 and keeps a Neutral rating on the shares after the company reported Q3 Yutrepia sales in line…
Liquidia price target raised to $40 from $33 at Wells Fargo
Wells Fargo raised the firm’s price target on Liquidia (LQDA) to $40 from $33 and keeps an Equal Weight rating on the shares. The firm found commentary on October demand…
Liquidia price target raised to $66 from $58 at Needham
Needham raised the firm’s price target on Liquidia (LQDA) to $66 from $58 and keeps a Buy rating on the shares. The company’s Q3 update “paints a more positive picture”…
Liquidia price target raised to $62 from $55 at Jefferies
Jefferies analyst Amy Li raised the firm’s price target on Liquidia (LQDA) to $62 from $55 and keeps a Buy rating on the shares after the company reported Q3 Yutrepia…
Liquidia price target raised to $87 from $70 at BTIG
BTIG analyst Julian Harrison raised the firm’s price target on Liquidia (LQDA) to $87 from $70 and keeps a Buy rating on the shares. Q3 results and October commercial metrics…
Liquidia reports Q3 EPS ($2.64), consensus 98c
Reports Q3 revenue $222.7M, consensus $214.15M. Litigation settlement, net was $389.7M for the three months ended September 30, 2026. Cash and cash equivalents totaled $396.1M as of September 30, 2026...
Liquidia Earnings Call Transcript: Q3 2026
Q3 YUTREPIA sales rose 31% QoQ to $222.7 million, with adjusted EBITDA reaching $140.5 million. Litigation is settled, while referral trends and clinical programs underpin continued growth plans.
Liquidia Earnings release: Q3 2026
Liquidia released its Q3 2026 earnings on November 10, 2026, summarizing the period's financial results.
Liquidia Quarterly report: Q3 2026
Liquidia has published its Q3 2026 quarterly earnings report on November 10, 2026.
Liquidia Slides: Q3 2026
Liquidia has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 10, 2026.
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and ...
Liquidia Corporation Reports Third Quarter 2026 Financial Results
MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challengi...
Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
MORRISVILLE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challengi...
Liquidia price target raised to $42 from $38 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on Liquidia (LQDA) to $42 from $38 and keeps a Neutral rating on the shares following a global litigation settlement with…
Liquidia price target raised to $65 from $58 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Liquidia (LQDA) to $65 from $58 and keeps a Buy rating on the shares after the company announced a global settlement with…
This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.
Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
MORRISVILLE, N.C., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challengi...
LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $LQDA--LQDA Investors with $100,000 in Losses Have Opportunity to Join Liquidia Corporation Fraud Investigation with SBS Law.
LQDA SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Liquidia Corporation
A court finding that Yutrepia infringed two valid claims of United Therapeutics' '327 patent has put the drug's PH-ILD indication and broader availability at risk. SueWallSt notifies investors of a pe...
